The Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen and submitted it to the Institute.
This appraisal is only looking at locally advanced or metastatic breast cancer that has progressed after only 1 chemotherapy regimen. A positive recommendation on eribulin for treating locally advanced or metastatic breast cancer in adults who have had 2 or more chemotherapy regimens is given in a separate NICE technology appraisal (TA423).
The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FAD has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5pm on Thursday 8 March 2018.
This page was last updated: 22 February 2018